EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry

Nadine Kutsch iD, Rudy Ligtvoet iD, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Dörfel, Jörg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al-Sawaf iD, Petra Langerbeins und 5 weitere

European Journal of Haematology · 2026-08 · 117 (2) · 351-357

DOI: 10.1111/ejh.70178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 14.04.2026. Verfasst von Nadine Kutsch und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Col…. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-bcl-2, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Within a dataset of the German CLL Study Group (GCLLSG) registry, 274 patients were allocated to a cohort with venetoclax and 888 to a cohort with BTKi (79 acalabrutinib, 809 ibrutinib), each as first administered targeted substance class within the documented treatment sequence. Venetoclax was administered as first‐line treatment in 152 of 274 patients (55.5%). After a median observation time of 14 months from the start of the first documented venetoclax treatment, the 1‐year event‐free survival (EFS) was 82.1% and the 1‐year overall survival (OS) was 94.2%. The 1‐year OS was 96.3% when venetoclax was given as first‐line treatment versus 92.1% when given for the first time in a later therapy line (HR 0.38, 95% CI 0.14–1.05). In the BTKi cohort, 351 of 888 patients (39.5%) received a BTKi as first‐line treatment. The median observation time was 34 months from the start of the first documented BTKi treatment, with a 3‐year EFS of 32.4% and a 3‐year OS of 78.5%. The 3‐year OS for a BTKi in first‐line was 87.9% compared to 73.8% in a later therapy line (HR 0.43, 95% CI 0.30–0.61). Our analysis suggests better survival outcomes when these agents are used as first‐line therapy with the caveat that patients treated in later therapy lines typically exhibit more advanced disease and a poorer general condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsHumansRegistriesFemaleMaleAgedTreatment OutcomeMiddle AgedAged, 80 and overBridged Bicyclo Compounds, HeterocyclicSulfonamidesAdenineAdultBenzamidesPiperidinesPyrazines

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2BTK protein, humanBridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamidesAntineoplastic AgentsibrutinibBCL2 protein, human

Autor:innen und Institutionen

  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Practice for Blood and Cancer Diseases, Potsdam, Germany.
  • Practice for Hematology and Oncology, Dresden, Germany.
  • Oncozentrum, Dresden, Freiberg, Meißen, Germany.
  • Practice for Hematology and Oncology, Dortmund, Germany.
  • Practice for Hematology and Oncology, Würzburg, Germany.

ORCID-Profile: Nadine Kutsch, Rudy Ligtvoet, Othman Al-Sawaf

Zitieren

APA

Kutsch, N., Ligtvoet, R., Robrecht, S., Linde, H., Illmer, T., Dörfel, S., Lipke, J., Aldaoud, A., Schlag, R., Dengler, J., Al-Sawaf, O., Langerbeins, P., Cramer, P., Hallek, M., Eichhorst, B., Fischer, K., & Fink, A. (2026). Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry. European Journal of Haematology, 117(2), 351-357. https://doi.org/10.1111/ejh.70178

Vancouver

Kutsch N, Ligtvoet R, Robrecht S, Linde H, Illmer T, Dörfel S, et al. Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry. European Journal of Haematology. 2026;117(2):351-357. doi:10.1111/ejh.70178

BibTeX
@article{Kutsch2026,
  author = {Kutsch, Nadine and Ligtvoet, Rudy and Robrecht, Sandra and Linde, Hartmut and Illmer, Thomas and Dörfel, Steffen and Lipke, Jörg and Aldaoud, Ali and Schlag, Rudolf and Dengler, Jolanta and Al-Sawaf, Othman and Langerbeins, Petra and Cramer, Paula and Hallek, Michael and Eichhorst, Barbara and Fischer, Kirsten and Fink, Anna},
  title = {Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {2},
  pages = {351--357},
  doi = {10.1111/ejh.70178}
}
Kostenlos starten →